Aerovate Therapeutics Inc (AVTE) — Financial Flexibility Index
Aerovate Therapeutics Inc (AVTE) has a Financial Flexibility Index of -0.96x as of March 2025. Free cash flow of $-2.38 Million (operating CF $-2.38 Million minus capex $0.00) represents -1% of total liabilities ($2.49 Million). Check Aerovate Therapeutics Inc (AVTE) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Aerovate Therapeutics Inc Financial Flexibility Index (2019–2024)
Historical Financial Flexibility Index trend for Aerovate Therapeutics Inc across 6 annual periods. For the full cash flow conversion analysis, see Aerovate Therapeutics Inc cash conversion from operations.
Annual Financial Flexibility Index for Aerovate Therapeutics Inc (2019–2024)
Year-by-year free cash flow to debt coverage for Aerovate Therapeutics Inc. Explore debt repayment capacity of Aerovate Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -18.26x | $-71.20 Million | $-71.20 Million | $3.90 Million | ▼ -479.3% |
| 2023 | -3.15x | $-56.64 Million | $-56.78 Million | $17.96 Million | ▲ +30.7% |
| 2022 | -4.55x | $-38.93 Million | $-39.12 Million | $8.56 Million | ▲ +50.8% |
| 2021 | -9.24x | $-27.22 Million | $-27.40 Million | $2.94 Million | ▼ -2073.8% |
| 2020 | -0.43x | $-7.68 Million | $-7.86 Million | $18.06 Million | ▼ -17.0% |
| 2019 | -0.36x | $-2.60 Million | $-2.78 Million | $7.16 Million | — |